Twice-Yearly HIV prevention shot shows promise in women
NCT ID NCT06101329
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests a new long-acting injection called lenacapavir, given every 6 months, to prevent HIV in cisgender women in the US. About 253 women will receive either the injection or daily pills (Truvada) to compare how well the drug works in the body, its safety, and how acceptable it is. The goal is to see if a twice-yearly shot could be a convenient alternative to daily medication for HIV prevention.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
lenacapavir (injection and tablet) and emtricitabine/tenofovir disoproxil fumarate (Truvada)
What this could lead to
If successful, this could offer a convenient twice-yearly injection option for HIV prevention, reducing the need for daily pills.
What could go wrong
This is an early phase 2 study with only 253 women, so results may not apply to everyone. Side effects or low acceptability could limit its use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRE-EXPOSURE PROPHYLAXIS OF HIV INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cornell Clinical Trials Unit, New York Presbyterian Hospital - Weill Cornell Medicine
New York, New York, 10010, United States
-
Fenway Health
Boston, Massachusetts, 02215, United States
-
George Washington University Medical Faculty Associates
Washington D.C., District of Columbia, 20037, United States
-
Harlem Prevention Center CRS
New York, New York, 10027, United States
-
ICAP at Columbia University - Bronx Prevention Center
The Bronx, New York, 10451, United States
-
NC TraCS Institute - CTRC; University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, 27599, United States
-
Penn Prevention Research Unit
Philadelphia, Pennsylvania, 19104, United States
-
Ponce de Leon Center Clinical Research Site
Atlanta, Georgia, 30303, United States
-
Rutgers New Jesey Medical School - Clinical Research Center
Newark, New Jersey, 07103, United States
-
UAB, 1917 Research Clinic
Birmingham, Alabama, 35222, United States
-
UCSD Antiviral Research Center (AVRC)
San Diego, California, 92103, United States